Abstract Number: 0211 • ACR Convergence 2024
Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas
Background/Purpose: Patients with SLE have high rates of hospitalizations annually and require careful coordination of care in both the inpatient and outpatient setting. Prior analyses…Abstract Number: 2507 • ACR Convergence 2024
IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic, fibroinflammatory condition affecting almost all organs. It is a rare entity that is continuously being studied worldwide. It…Abstract Number: 0232 • ACR Convergence 2024
Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study
Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…Abstract Number: 0588 • ACR Convergence 2024
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…Abstract Number: 0662 • ACR Convergence 2024
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…Abstract Number: 0724 • ACR Convergence 2024
Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) is a group of vasculitis that affect small vessels. Includes Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with…Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…Abstract Number: 1020 • ACR Convergence 2024
Health Inequalities Exist Between the United States and Europe for Patients with Axial Spondyloarthritis
Background/Purpose: Structural differences exist between the healthcare systems in the United States (US) and Europe. In real-world clinical settings, we investigated whether these differences create…Abstract Number: 1107 • ACR Convergence 2024
Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
Background/Purpose: Pyrexia of Unknown Origin (PUO) is defined as a fever above 38.3°C recorded on several occasions, that evades diagnosis for at least 3 weeks.…Abstract Number: 1251 • ACR Convergence 2024
Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…Abstract Number: 1877 • ACR Convergence 2024
Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities
Background/Purpose: Rheumatoid Arthritis (RA) exhibits varied epidemiological patterns across states in the United States, influencing disability-adjusted life years (DALYs), incidence rates, prevalence, and mortality. This…Abstract Number: 0139 • ACR Convergence 2024
Analysis of Rheumatoid Arthritis Epidemiology in Mexico Using the GBD 2019 Study and Forecasting Future Trends for 2030 and 2040
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder related to disability and premature mortality. Nowadays, the burden of RA is needed for healthcare…Abstract Number: 1879 • ACR Convergence 2024
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
- 1
- 2
- 3
- …
- 5
- Next Page »